Fibrosis and the Fontan

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

February 11, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Single-ventricle
Interventions
DRUG

Spironolactone

Spironolactone is a mild diuretic. Drug dosage will be those used clinically and per the CHOP formulary: 3 mg/kg/day in divided doses every 6-24 hours; the drug will be weight adjusted every \~0.5 kg with a maximum dosage of 200 mg/24 hours. Maximum single dose is 100 mg. Spironolactone, the aldosterone antagonist to be utilized in Specific Aim 2 of this study, is FDA approved, has been on the market for many years and is routinely administered to all types of children with congenital heart disease including SV patients. The choice of which patient this should be administered to is up to the clinician and their patients and therefore, not all SV patients are on this medication.

Trial Locations (1)

19130

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Children's Hospital of Philadelphia

OTHER